보라 구

보라 구

Auto-generated profile, based on publicly available information

보라 구

질병관리청 진단분석국 매개체분석

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2026
Verified
Journal Article
Open access
PDF file
HJHaneul Jung
Haneul Jung
보구보라 구
보라 구
일김일환 김
일환 김
희이희일 이
희일 이
정하늘, 구보라, 김일환, 이희일. Public Health Weekly Report 2026;19:1037-51. https://doi.org/10.56786/PHWR.2026.19.26.1

Verified
Journal Article
Open access
PDF file
HJHaneul Jung
Haneul Jung
BKBora Ku
Bora Ku
SLSeon-Young Lee
Seon-Young Lee
IKIl-Hwan Kim
Il-Hwan Kim
SLSang Eun Lee
Sang Eun Lee
Plasmodium vivax malaria remains an important public health concern in the Republic of Korea, which targets elimination by 2030. Primaquine is essential for radical cure and relapse prevention; its metabolic activation involves cytochrome P450 2D6 (CYP2D6). CYP2D6 genetic variation may influence metabolic capacity and contribute to primaquine treatment response differences. We examined CYP2D6 genotype and predicted metabolizer phenotype distributions among Korean patients with P. vivax malaria, exploring their associations with recurrence. We analyzed 106 P. vivax specimens collected by the Korea Disease Control and Prevention Agency during 2016–2026. Activity scores and predicted metabolizer phenotypes were derived from genotypes. Allele and phenotype frequencies were compared using Fisher’s exact test; activity scores were compared using the Mann–Whitney U test. Compared with the non-recurrence group, the recurrence group had a significantly higher *10B allele frequency (p = 0.002) and proportion of intermediate metabolizers (p = 0.029), and a significantly lower *1 allele frequency (p = 0.001) and activity score (p = 0.026). The reduced-function *10B allele and intermediate metabolizer phenotype were common in Korean patients with P. vivax malaria. Reduced predicted CYP2D6 metabolic capacity may be associated with recurrence, supporting prospective evaluation of CYP2D6 variation and primaquine treatment response.

17 March 2025 in Public Health Weekly Report
Verified
Journal Article
Open access
PDF file
보구보라 구
보라 구
HJHaneul Jung
Haneul Jung
현신현일 신
현일 신
명이명노 이
명노 이
정주정원 주
정원 주
희이희일 이
희일 이
구보라, 정하늘, 신현일, 이명노, 주정원, 이희일. Public Health Weekly Report 2025;18:584-95. https://doi.org/10.56786/PHWR.2025.18.14.2

8 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
HJHaneul Jung
Haneul Jung
HSHyun-Il Shin
Hyun-Il Shin
BKBora Ku
Bora Ku
EPEsther Park
Esther Park
MLMyoung-Ro Lee
Myoung-Ro Lee
HLHee Il Lee
Hee Il Lee
In the Republic of Korea (ROK), chloroquine is the first-line treatment for Plasmodium vivax (P. vivax), and primaquine is also prescribed to prevent relapse. For Plasmodium falciparum (P. falciparum), atovaquone-proguanil, pyronaridine-artesunate, and mefloquine are recommended. This study monitored drug resistance genes in blood samples collected from patients with P. vivax (soldiers, relapsed, and imported) and P. falciparum (soldiers and civilians) between 2022 and 2025. In P. vivax, several Pvmdr-1 mutations showed high prevalence, with S515R, G698S, L845F, M908L, T958M, and F1076L observed in nearly all isolates, while T529 and E1233 mutation showed moderate prevalence. S513R, Y541C, A829V, and S1358 mutation were occasionally identified, all of which were imported or soldiers receiving prophylactic chemotherapy. Significant differences in mutation prevalence were identified among groups (p < 0.05). However, no significant temporal trends were observed. In P. falciparum, the Y184F mutation in Pfmdr-1 was highly prevalent, and A675V mutation in PfK13 was detected only in soldiers. Group comparisons revealed significant differences (p < 0.05), whereas temporal trends were not observed. Because drug resistance gene mutations can be closely linked to treatment, surveillance of drug resistance genes is expected to contribute to malaria eradication in the ROK through providing basic information related to treatment.